The ADHD Drug That Might Actually Help Your Anxiety Too
Otsuka's centanafadine just posted positive Phase 3b results in adults with both ADHD and anxiety, hitting endpoints on both conditions with a single pill. With an FDA decision due July 24, this triple-reuptake inhibitor could reshape how doctors treat one of psychiatry's most common (and frustrating) combos.
About half of adults with ADHD also have an anxiety disorder. For decades, treating both at the same time has been a mess. Stimulants can make anxiety worse. Anti-anxiety meds don't touch ADHD. So patients end up juggling two or three prescriptions, hoping the side effects don't cancel out the benefits.
Otsuka thinks it has a better idea: one pill that handles both.
The Results That Just Dropped
On June 25, 2026, Otsuka released topline data from a Phase 3b trial of centanafadine XR in 315 adults who had both ADHD and a comorbid anxiety disorder (generalized anxiety, social anxiety, or both). The drug was dosed at 280 mg once daily for eight weeks, tested against placebo in a randomized, double-blind design.
The headline numbers are strong. On the primary measure of ADHD symptoms (a scale called AISRS, where lower is better), patients on centanafadine improved by 18.5 points versus 12.6 for placebo. That's a treatment difference of nearly 6 points, with a p-value below 0.0001. Translation: the drug clearly worked for ADHD, and the result wasn't a fluke.
But the more interesting number is on anxiety. Using the Hamilton Anxiety Rating Scale, centanafadine patients improved by 12.5 points compared to 10.6 for placebo. That's a smaller gap (about 2 points), but it was statistically significant at p = 0.02. In a field where most ADHD drugs either ignore anxiety or make it worse, even a modest improvement matters.
Perhaps most compelling: the ADHD benefit showed up as early as week one and held steady through the full eight weeks.
Why This Drug Is Different
Most ADHD medications fall into two buckets. Stimulants (think Adderall, Ritalin) boost dopamine and norepinephrine. They work fast and they work well, but they're controlled substances with real abuse potential, and they can crank up anxiety in vulnerable patients. Non-stimulants like atomoxetine (the generic formerly known as Strattera) are gentler, but they only target norepinephrine. Many doctors find them slower and less potent.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Centanafadine plays a different game entirely. It's a triple reuptake inhibitor, blocking the recycling of three brain chemicals: norepinephrine, dopamine, and serotonin. Think of it like a three-lane highway instead of the usual one or two. The norepinephrine and dopamine activity handles core ADHD symptoms (attention, impulsivity, executive function). The serotonin piece, typically the domain of antidepressants and anti-anxiety meds, is what gives centanafadine its unusual anxiety-friendly profile.
In lab terms, it hits the norepinephrine transporter hardest (IC₅₀ around 6 nM), dopamine next (38 nM), and serotonin last (83 nM). That hierarchy is deliberate: enough serotonin activity to matter, not so much that it dominates.
Otsuka calls it a "non-stimulant," but pharmacologically it's more like a stimulant wearing a non-stimulant disguise. It engages dopamine (like stimulants do) but without the euphoria, craving, or abuse signals that earned amphetamines their Schedule II classification. In a 52-week safety study, researchers found no reports of euphoric mood or drug craving.
The Competitive Landscape Is Getting Crowded
Centanafadine isn't entering an empty market. The non-stimulant ADHD category is actually the fastest-growing segment, expanding at roughly 7-9% annually. Generic atomoxetine is the workhorse: cheap, familiar, and on every formulary. Supernus's Qelbree (viloxazine ER) is the current branded darling, approved for both kids and adults, and growing fast.
So where does centanafadine fit? Picture the non-stimulant market as a restaurant menu. Atomoxetine is the reliable house salad; everyone knows it, it's affordable, nobody gets excited. Qelbree is the trendy new entrée that's been getting great reviews. Centanafadine wants to be the chef's special: pricier, but with a unique flavor profile that justifies the splurge for the right customer.
That "right customer" is the anxious adult with ADHD. No other non-stimulant has dedicated Phase 3 data in this specific population. That's centanafadine's sharpest edge.
The Road to Approval (and Beyond)
Otsuka filed its New Drug Application for centanafadine in January 2025, covering children, adolescents, and adults with ADHD. The FDA granted priority review, which is a signal that the agency considers it a potentially significant advance. The PDUFA target date (the FDA's deadline to make a decision) is July 24, 2026, meaning we're less than a month away from a verdict.
The NDA is backed by four pivotal Phase 3 trials spanning all age groups, plus a year-long safety study in adults. The new Phase 3b anxiety data isn't part of the original NDA package, but it strengthens the overall narrative. And it could influence what the FDA allows Otsuka to say on the label about patients with comorbid anxiety.
That label language is actually the biggest commercial wildcard. If the FDA lets Otsuka reference the anxiety data prominently, psychiatrists will have a clear, evidence-backed reason to reach for centanafadine over atomoxetine or Qelbree in anxious patients. If the label stays narrow, Otsuka can still talk about the data at conferences and in medical education, but the marketing punch weakens considerably.
What Investors Should Watch
The July 24 PDUFA date is the obvious catalyst. Approval seems likely given the breadth of data, but the devil is in the details: scheduling (will the DEA classify it as controlled?), label breadth, and any post-marketing requirements.
After that, it's all about payer access. Insurance companies love to make patients try cheaper options first. If centanafadine gets stuck behind step-therapy requirements ("try generic atomoxetine, then come back"), uptake will be slow. Otsuka's existing neuroscience sales infrastructure in the U.S. should help, but the real test is whether the anxiety data can convince formulary committees that this drug deserves a clear lane.
Industry analysts project centanafadine and a handful of other late-stage ADHD drugs could collectively add about $395 million in sales by 2032. That's meaningful but not blockbuster territory, at least not yet.
The Bottom Line
For years, adults with ADHD and anxiety have been stuck choosing between drugs that help one condition but might worsen the other. Centanafadine's Phase 3b data suggests a single pill can meaningfully improve both, without the abuse concerns that come with stimulants. The effect on anxiety is modest, not miraculous. But in a treatment landscape full of compromises, "modest" might be exactly what millions of patients have been waiting for.
The FDA's answer comes in less than a month. Stay tuned.
Clinical & Regulatory
5 min read
Sarepta's Worst Week: A Black Box Warning and 500 Pink Slips
Sarepta slapped a black box warning on its flagship gene therapy Elevidys after fatal liver failures in young patients, then cut 36% of its workforce in the same breath. The moves signal a company (and an industry) at a crossroads.
